Ribociclib tablets (Kisqali) | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Ribociclib tablets (Kisqali) - selected U.S. label sections

Product / population: KISQALI oral tablets for breast cancer; not a combined letrozole package instruction.
Renal measure: eGFR in mL/min/1.73 m2; severe category as specified by the label.

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Renal dose comments

Mild or moderate renal impairment does not require adjustment. For severe impairment, the recommended starting dose is 200 mg once daily. Preserve the treatment cycle of 21 days on treatment followed by 7 days off, rather than converting this into continuous daily therapy.

Scope and monitoring

The concomitant endocrine therapy, toxicity modifications, ECG and electrolyte monitoring remain separate requirements. This summary does not assign a hemodialysis regimen.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Ribociclib tablets (Kisqali) - selected U.S. label sections

KISQALI oral tablets for breast cancer; not a combined letrozole package instruction.

Renal method: eGFR in mL/min/1.73 m2; severe category as specified by the label.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

Ribociclib tablets (Kisqali) - selected U.S. label sections

KISQALI oral tablets for breast cancer; not a combined letrozole package instruction.

Method: eGFR in mL/min/1.73 m2; severe category as specified by the label.

Renal dose comments Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope Ribociclib tablets (Kisqali) - selected U.S. label sections

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8

Product and population scope

KISQALI oral tablets for breast cancer; not a combined letrozole package instruction.

RDM32-ribociclib-kisqali-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

Ribociclib tablets (Kisqali) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · KISQALI oral tablets for breast cancer; not a combined letrozole package instruction.

Renal method: eGFR in mL/min/1.73 m2; severe category as specified by the label.
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal dose comments

RDM32-ribociclib-kisqali-1 · Source locator: 2.1; 2.2, Severe Renal Impairment; 8.7

Scope and monitoring

The concomitant endocrine therapy, toxicity modifications, ECG and electrolyte monitoring remain separate requirements. This summary does not assign a hemodialysis regimen.

RDM32-ribociclib-kisqali-2 · Source locator: 2; 5.3; 8.7

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8
Retrieved: 2026-09-05
DailyMed Set ID: aaeaef94-f3f5-4367-8ea2-b181d7be2da8
Renal-function method: eGFR in mL/min/1.73 m2; severe category as specified by the label.
Source date/version: Revision not captured; retrieval date is not the revision date.
Hash meaning: SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256: 6082d05b25510bc3da6e7766d663e64719c072b73edacf13e6d613be2b905299

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8
Source retrieval: 2026-09-05. This is not the source publication or label revision date.
Original source type: multisource addition
Local text SHA-256: 632c1f8545b10d1ad042df540183ee6df0ea50b506d6f6facbf14de1f7ff7ceb
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report